A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Recruiting

Phase 1

Phase 2

RevumenibA Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Sponsor:

Syndax Pharmaceuticals

Code:

NCT04065399

Conditions

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Mixed Lineage Acute Leukemia

Mixed Phenotype Acute Leukemia

Acute Leukemia of Ambiguous Lineage

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

revumenib

cobicistat

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-26. This information was provided to ClinicalTrials.gov by Syndax Pharmaceuticals on 2025-11-10.